Drug: Copanlisib (Aliqopa, Bayer)
Status: Granted accelerated approval to treat patients with relapsed follicular lymphoma who have received at least 2 prior treatments
Significant Information:
- Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor that hinders several key cell-signaling pathways, including B-cell receptor signaling, CXCL12-mediated chemotaxis of malignant B cells and NFkappaB signaling in lymphoma cell lines.
- The approval was based on the phase 2, single-arm CHRONOS-1 trial of